The challenges in commercialisation of Probiotic API manufacturing
Joe Liu A B , Brendan Cook A and Shaun Roux AMicrobiology Australia 41(2) 82-85 https://doi.org/10.1071/MA20021
Published: 19 May 2020
Abstract
The concept of probiotics is well known and has developed into a high value commodity in recent times. Despite the ever-expanding number of probiotic products on our pharmacy, health food and supermarket shelves, the probiotic culture active ingredient has always been imported until now. In 2019, Probiotics Australia Pty Ltd opened Australia’s first and only Therapeutic Goods Administration/current Good Manufacturing Practice (TGA/cGMP) certified facility dedicated to the manufacture of probiotic active ingredients. This article outlines the significant export demand for Australian-made health products and the lengths to which Probiotics Australia have gone to create a facility to meet needs of the probiotics research, commercialisation and consumer market today and into the future.
References
[1] Research and Markets (2019) Probiotics market by application (functional food & beverages [dairy products, non-dairy beverages, infant formula, cereals], dietary supplements, feed), ingredient (bacteria, yeast), form (dry, liquid), end user, and region-global forecast to 2023. Researchandmarkets.com[2] Wynn, K., and Sebastian, B. (2019) Growth opportunities for Australian food and agribusiness – economic analysis and market sizing. CSIRO Futures.
[3] Crittenden, R. et al.. (2005) Probiotic Research in Australia, New Zealand and the Asia-Pacific Region. Curr. Pharm. Des. 11, 37–53.
| Probiotic Research in Australia, New Zealand and the Asia-Pacific Region.Crossref | GoogleScholarGoogle Scholar | 15638751PubMed |
[4] PIC/S (2009) Guide to good manufacturing practice for medicinal products, part II. https://www.tga.gov.au/sites/default/files/manuf-pics-gmp-medicines-part2.pdf
